cyprotex
the ADME Tox specialists
welcome to cyprotex

Investor News

July 14, 2010 - AGM Statement

Cyprotex PLC ("Cyprotex" or the "Company")

Cyprotex (AIM:CRX), the drug discovery technology and information company, will hold its Annual General meeting today. At that meeting, Steve Harris, Chairman, will make the following comments:

"In 2009 we delivered a resilient performance in a difficult market. Revenues hit £5m for the second successive year and we also delivered our second year of profitability. We doubled the number of strategic customers and added 20 new customers in total.

"In the current year, Cyprotex has experienced a strong second quarter and this momentum has continued into July. The Company's revenue and EBITDA performance is in line with market expectations. Furthermore, the Company will open a new laboratory in the coming weeks which will double capacity and allow the launch of our new toxicology offerings."

Cyprotex expects to announce its interim results for the six months to 30 June 2010 on Thursday 12 August 2010.


For further information:
Cyprotex PLC
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Tel: +44 (0) 1625 505 100
ir@cyprotex.com
www.cyprotex.com

Singer Capital Markets Ltd
Shaun Dobson
Claes Spång
Tel: +44 203 205 7500
www.singercm.com

Financial Dynamics
Ben Brewerton / Ben Atwell / Mo Noonan
Tel: +44 (0) 20 7831 3113
cyprotex@fd.com
www.fd.com

view all the latest news +
2013 archive +
2012 archive +
2011 archive +
2010 archive +
2009 archive +
2008 archive +
2007 archive +
2006 archive +
2005 archive +
2004 archive +
2003 archive +
2002 archive +
contact

Find out more about us.

Investor Relations
Anthony Baxter/Mark Warburton

Call on +44 1625 505100

contact
careerscontactlegalprivacy
This website was last updated
on 16th April 2014
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.